阿尔凯默斯 ALKS 深 沪
等待开盘 05-21 09:30:00 美东时间
36.98
-0.020
-0.05%
华盛通- 最 高37.94
- 今 开37.21
- 成交量 181.79万股
- 最 低 36.88
- 昨 收 37.00
- 总市值 61.64亿
- 52周最高 39.56
- 市盈率 静 25.82
- 换手率 1.09%
- 52周最低 25.165
- 委 比 95.65%
- 总股本 1.67亿
- 历史最高 79.041
- 量 比 0.91
- 振 幅 2.86%
- 历史最低 10.311
- 每 手 1
- 风险率 2.64%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
Alkermes Gains Momentum After Sleep Disorder Trial Clears Key Hurdles
Alkermes shares climbed after phase 3 LUMRYZ data met key endpoints in idiopathic hypersomnia as analysts raised price targets.
05-13 02:27
Alkermes posts late-stage trial win for Lumryz in new sleep disorder
Alkermes (ALKS) shares gained in the premarket on Tuesday after the company announced that its sleep disorder therapy Lumryz reached the primary goal in a late-stage trial for patients with idiopathic...
05-12 20:39
美股大行评级 | 潜在涨幅20%！15家机构集体上调AMD目标价；Lumentum、神经分泌生物科学、伊顿公司、美国电力等获多家大行上调目标价
今日重点评级关注：Citizens：维持Avalo Therapeutics"跑赢大市"评级，目标价从52美元升至62美元；BTIG：维持Avalo Therapeutics"买入"评级，目标价从40美元升至58美元
05-07 12:37
Wells Fargo Maintains Overweight on Alkermes, Raises Price Target to $44
Wells Fargo analyst Benjamin Burnett maintains Alkermes (NASDAQ:ALKS) with a Overweight and raises the price target from $43 to $44.
05-06 21:36
财报速睇 | 阿尔凯默斯 2026财年Q1营收3.93亿美元，同比增长28.2%；归母净利润亏损0.66亿美元，由盈转亏
华盛资讯5月6日讯，阿尔凯默斯公布2026财年Q1业绩，公司Q1营收3.93亿美元，同比增长28.2%，归母净利润亏损0.66亿美元，由盈转亏。
05-06 06:53
财报速睇 | 阿尔凯默斯 2026财年Q1营收3.93亿美元，同比增长28.2%；归母净利润亏损0.66亿美元，由盈转亏
华盛资讯5月5日讯，阿尔凯默斯公布2026财年Q1业绩，公司Q1营收3.93亿美元，同比增长28.2%，归母净利润亏损0.66亿美元，由盈转亏。
05-05 20:43
Alkermes Raises FY2026 GAAP EPS Guidance from $(0.80)-$(0.68) to $(0.52)-$(0.41) vs $(0.54) Est; Affirms FY2026 Sales Guidance of $1.730B-$1.840B vs $1.798B Est
Financial Expectations for 2026In connection with the purchase price accounting related to the acquisition of Avadel, the company is updating certain non-cash elements of its 2026 full year financial expectations,
05-05 19:18
Earnings Scheduled For May 5, 2026
Companies Reporting Before The Bell • Repligen (NASDAQ:RGEN) is projected to re...
05-05 19:12
Alkermes Q1 EPS $(0.40) Beats $(0.52) Estimate, Sales $392.911M Beat $359.848M Estimate
Alkermes (NASDAQ:ALKS) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.52) by 23.08 percent. This is a 407.69 percent decrease over earnings of $0.13 per share from the
05-05 19:08
